Ultragenyx Pharmaceutical Inc
Research Ultragenyx Pharmaceutical Inc (RARE) on Bullrun: market cap USD 3.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRARE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.02B
- Financial periodFY2025
- RevenueUSD 673.00M
- Revenue growth20.2%
- Net income-USD 575.00M
- Free cash flow-USD 472.00M
Valuation Snapshot
latest market cap is USD 3.02B.
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia;
Frequently asked questions
What is Ultragenyx Pharmaceutical Inc's market cap?
Ultragenyx Pharmaceutical Inc's market capitalization is USD 3.02B.
What does Ultragenyx Pharmaceutical Inc do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the...